These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 7987999)
1. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Herman EH; Zhang J; Ferrans VJ Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Herman EH; el-Hage A; Ferrans VJ Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116 [TBL] [Abstract][Full Text] [Related]
5. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. Zhang J; Herman EH; Ferrans VJ Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559 [TBL] [Abstract][Full Text] [Related]
6. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Dardir M; Herman EH; Ferrans VJ Cancer Chemother Pharmacol; 1989; 23(5):269-75. PubMed ID: 2495862 [TBL] [Abstract][Full Text] [Related]
7. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Saad SY; Najjar TA; Al-Rikabi AC Pharmacol Res; 2001 Mar; 43(3):211-8. PubMed ID: 11401411 [TBL] [Abstract][Full Text] [Related]
8. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460 [TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. Zhang J; Clark JR; Herman EH; Ferrans VJ J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552 [TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. van Acker SA; Kramer K; Voest EE; Grimbergen JA; Zhang J; van der Vijgh WJ; Bast A Cancer Chemother Pharmacol; 1996; 38(1):95-101. PubMed ID: 8603459 [TBL] [Abstract][Full Text] [Related]
11. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Herman EH; Ferrans VJ Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Herman EH; Zhang J; Chadwick DP; Ferrans VJ Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322 [TBL] [Abstract][Full Text] [Related]
13. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159). Herman EH; Ferrans VJ; Bhat HB; Witiak DT Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714 [TBL] [Abstract][Full Text] [Related]
14. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Alderton P; Gross J; Green MD Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Herman EH; Ferrans VJ Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268 [TBL] [Abstract][Full Text] [Related]
16. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Herman EH; Ferrans VJ Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310 [TBL] [Abstract][Full Text] [Related]
17. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199 [TBL] [Abstract][Full Text] [Related]
19. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630 [TBL] [Abstract][Full Text] [Related]
20. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]